Sanofi, JnJ, Amgen in talks to acquire Horizon Therapeutics

Published On 2022-12-01 11:03 GMT   |   Update On 2022-12-01 11:03 GMT
Advertisement

Bengaluru: Horizon Therapeutics Plc said on Tuesday its board was engaged in highly preliminary discussions with three pharmaceutical giants for potential takeover offers, sending its shares surging 31 percent in extended trading.

The biotech company, with a market capitalization of about $18 billion, is in talks with Amgen Inc, Sanofi and Johnson & Johnson unit Janssen Global Services. Horizon, which makes drugs for rare, autoimmune, and severe inflammatory diseases, however, added there can be no certainty that any offer will be made. The three firms have been active in deal-making this year.
Advertisement
Amgen acquired ChemoCentryx in a $4 billion deal in October, while J&J earlier this month announced a $16.6 billion bid for Abiomed. Sanofi earlier this year completed the buyout of immuno-oncology company Amunix Pharmaceuticals for around $1 billion.
Amgen declined to comment on the talks, while Sanofi and Janssen Global were not immediately available.
Horizon expects over $4 billion in global annual peak sales for its biggest drug Tepezza, which is used to treat thyroid eye disease. It has also estimated more than $1.5 billion in peak U.S. annual sales of its second largest drug Krystexxa, used for the treatment of gout that is not controlled by other medicines.
Tepezza had generated nearly $1.5 billion in the nine months ended Sept. 30, a growth of 37 percent from last year, while Krystexxa garnered $500 million, up 27 per centfrom the prior year.

Read also: Patent infringement: Johnson and Johnson sues Amgen over plan to sell drug similar to Stelara

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News